胃癌肝转移诊断与综合治疗中国专家共识(2019版)
肝脏是胃癌血行转移最常见的靶器官。胃癌肝转移的总体发生率约9.9%~18.7%,其中同时性胃癌肝转移的比例约73.3%,异时性胃癌肝转移的比例约26.7%。胃癌根治术后发生肝脏转移的中位间隔时间约14个月,中位生存时间约11个月,5年存活率<20%。经原发灶、转移灶根治性切除的胃癌肝转移病人5年存活率可提高至23.8%。
文献综述|胃癌肝转移治疗现状
肝脏是晚期胃癌常见的远处转移器官,文献报道4%~14%的胃癌发生肝转移。多年来,学者们一致认为发生肝转移的胃癌组织通常分化差,转移灶多发且常累及两个肝叶,同时存在原发灶对邻近器官直接侵犯以及腹膜播散、淋巴结转移。因此,胃癌肝转移(GCLM)是晚期胃癌致死的主要原因之一。
标准残肝体积预测肝癌合并肝硬化患者半肝切除术后肝功能衰竭的临床研究
本研究目的是探讨肝细胞癌(HCC)合并肝硬化患者肝切术标准残肝体积(the standard remnant liver vol⁃ ume,SRLV)的安全临界值及其评估术后肝功能衰竭(post-hepatectomy liver failure,PHLF)的效能。
肝细胞癌外照射放疗的研究进展
肝细胞癌(HCC)的根治性治疗方式主要为行手术切除、肝移植或消融术。然而,就诊时仅少数病 例为可切除病变。随着放疗技术的发展,外照射放疗在HCC治疗中的应用越来越广泛。大量研究表明,放疗对肝功能良好的各 期别肝癌均具有明显疗效。
Cancer, Hepatoblastoma
Hepatoblastomas are the most common primary malignant liver tumor in pediatric patients. Over the last 3 decades, the treatment has advanced with neo-adjuvant chemotherapy now the standard of care for most cases. Neo-adjuvant chemotherapy and surgical resection produce a cure rate of approximately 70%, a vast improvement over the dismal 30% cure rate in the 1970s. Prognosis is based on many factors including alphafetoprotein levels, age at the time of diagnosis, completeness of resection, and clinical stage of the disease.
Hepatocellular carcinoma in children: hepatic resection and liver transplantation
Different strategies have been explored to convert unresectable HCC into resectable tumors by extending criteria for surgical treatment and/or associating multi-modal treatments, such as systemic and local-regional therapy, but universal recommendation needs to be defined yet. The purpose of this review is to outline the role of different surgical approaches, including hepatic resection and liver transplantation, in pediatric HCC with or without underlying chronic liver disease.